Pruritus Therapeutic Market by Disease Type and Geography - Forecast and Analysis 2021-2025

The pruritus therapeutic market share is expected to increase by USD 4.01 billion from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 5.64%.

This pruritus therapeutic market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers pruritus therapeutic market segmentations by disease type (renal pruritus, cholestatic pruritus, hematologic pruritus, endocrine pruritus, and oncological pruritus) and geography (North America, Europe, and APAC). The pruritus therapeutic market report also offers information on several market vendors, including Abbott Laboratories, Allergan Plc, Astellas Pharma Inc., Cipla Inc., GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi, and Sun Pharmaceutical Industries Ltd. among others.

What will the Pruritus Therapeutic Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Pruritus Therapeutic Market Size for the Forecast Period and Other Important Statistics

 

Pruritus Therapeutic Market: Key Drivers, Trends, and Challenges

The increasing prevalence of pruritus is notably driving the pruritus therapeutic market growth, although factors such as poor patient adherence due to inadequate information on drug usage may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the pruritus therapeutic industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Pruritus Therapeutic Market Driver

The increasing prevalence of pruritus is a major factor driving the global pruritus therapeutic market share growth. Pruritus is one of the common symptoms in dermatology. It occurs in various disease conditions, namely hematology, renal, cholestatic, endocrine, and oncology. The growing prevalence of these diseases indirectly increases the pool of pruritus patients. This indicates a high scope for vendors to increase their business by developing novel pruritus therapeutic, which primarily drives the growth of the global pruritus therapeutic market during the forecast period. Approximately 12 million people in the US have psoriasis, and about 7.5 million are diagnosed with one or other forms of skin diseases that are accompanied by pruritus. Owing to the high prevalence of pruritus, the demand for pruritus therapeutics is expected to grow during the forecast period. Owing to the growing prevalence of pruritus and skin diseases, vendors are investing in R&D to develop therapeutic agents for pruritus, thereby driving the market growth.

Key Pruritus Therapeutic Market Trend

The incorporation of novel technology for product development is another factor supporting the global pruritus therapeutic market share growth. The incorporation of novel technologies in the development of products for the treatment of fungal infections, including pruritus, is one of the upcoming trends in the market. For instance, Merz Pharmaceuticals' ONMEL, which contains the active ingredient itraconazole, was developed by using the Meltrex technology of Abbott. The use of this technology makes the drug more effective and bioavailable in a tablet form by allowing otherwise poorly soluble drugs. Similarly, Celtic Pharmaceutical is engaged in the development of TDT-067, with terbinafine as the active ingredient and Transferosomes, a proprietary drug delivery technology originally developed by IDEA. Celtic Pharma acquired it in February 2006. Thus, the use of new technologies for the development and delivery of drugs helps in increasing its efficacy, thus providing better treatment options. Such technological advances will drive the growth of the market in the positive direction.

Key Pruritus Therapeutic Market Challenge

The poor patient adherence due to inadequate information on drug usage will be a major challenge for the global pruritus therapeutic market share growth during the forecast period. In the generic-heavy pruritus drugs market, nearly half of the treatment failures happen because of inadequate patient compliance. It has been observed that the patient outcome at even specialist centers is not positive as the treatment is not administered properly. The primary reason behind the treatment failure is the inadequate time spent by physicians in educating the individuals about various pruritus-causing diseases and medications for these conditions. Secondly, the patient pool attaches less seriousness to the indication as it is not life-threatening in most cases. Also, the extent of side effects and the threat of toxicity associated with pruritus drugs increases as individuals are not fully aware of the proper drug usage. In most cases, individuals are not aware that applying topical steroids more than twice a day increases the chances of side effects, making the therapy more expensive and reducing the efficacy of the drugs. Such inadequate information about the disease and drug usage reduces patient compliance with the drug regimen, thereby hampering the market growth.

This pruritus therapeutic market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.

Parent Market Analysis

Technavio categorizes the global pruritus therapeutic market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the pruritus therapeutic market during the forecast period.

Who are the Major Pruritus Therapeutic Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

• Abbott Laboratories
• Allergan Plc
• Astellas Pharma Inc.
• Cipla Inc.
• GlaxoSmithKline Plc
• Merck & Co. Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi
• Sun Pharmaceutical Industries Ltd.

This statistical study of the pruritus therapeutic market encompasses successful business strategies deployed by the key vendors. The pruritus therapeutic market is fragmented and the vendors are deploying growth strategies such as R&D, technological innovations, market expansion, investments, and distribution networks to compete in the market.

Product Insights and News

• Abbott Laboratories- It is an injectable drug which is used to treat adults with moderate to severe chronic plaque psoriasis.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The pruritus therapeutic market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Pruritus Therapeutic Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the pruritus therapeutic market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

The value chain of global pharmaceuticals market includes the following core components:

• Inputs
• Inbound logistics
• Operations
• Outbound logistics
• Marketing and sales
• Service
• Support activities
• Innovation

The report has further elucidated on other innovative approaches being followed by manufacturers to ensure a sustainable market presence.

Which are the Key Regions for Pruritus Therapeutic Market?

For more insights on the market share of various regions Request for a FREE sample now!

38% of the market's growth will originate from North America during the forecast period. US is the key market for pruritus therapeutic market in North America. Market growth in this region will be slower than the growth of the market in APAC.

The growing prevalence of various diseases such as chronic renal failure, cirrhosis, atopic eczema, psoriasis, and other diseases that cause pruritus will facilitate the pruritus therapeutic market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

What are the Revenue-generating Disease Type Segments in the Pruritus Therapeutic Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The pruritus therapeutic market share growth by the renal pruritus segment will be significant during the forecast period. Renal pruritus is observed in individuals with chronic renal failure and is predominantly seen in individuals receiving hemodialysis. The growing incidence of chronic kidney failure will continue leading to a higher patient pool of pruritus, thereby driving the market growth.

This report provides an accurate prediction of the contribution of all the segments to the growth of the pruritus therapeutic market size and actionable market insights on post COVID-19 impact on each segment.

 

Pruritus Therapeutic Market Scope
Report Coverage	Details
Page number	120
Base year	2020
Forecast period	2021-2025
Growth momentum & CAGR	Accelerate at a CAGR of 5.64%
Market growth 2021-2025	$ 4.01 billion
Market structure	Fragmented
YoY growth (%)	5.40
Regional analysis	North America, Europe, and APAC
Performing market contribution	North America at 38%
Key consumer countries	US, UK, Japan, Germany, and China
Competitive landscape	Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled	Abbott Laboratories, Allergan Plc, Astellas Pharma Inc., Cipla Inc., GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi, and Sun Pharmaceutical Industries Ltd.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Pruritus Therapeutic Market Report?

• CAGR of the market during the forecast period 2021-2025
• Detailed information on factors that will drive pruritus therapeutic market growth during the next five years
• Precise estimation of the pruritus therapeutic market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the pruritus therapeutic industry across North America, Europe, and APAC
• A thorough analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of pruritus therapeutic market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch